168 related articles for article (PubMed ID: 32104474)
1. Effect of Kupffer cells depletion on ABC phenomenon induced by Kupffer cells-targeted liposomes.
Lai C; Li C; Liu M; Qiu Q; Luo X; Liu X; Hu L; Deng Y; Song Y
Asian J Pharm Sci; 2019 Jul; 14(4):455-464. PubMed ID: 32104474
[TBL] [Abstract][Full Text] [Related]
2. Use of Dual-Ligand Modification in Kupffer Cell-Targeted Liposomes To Examine the Contribution of Kupffer Cells to Accelerated Blood Clearance Phenomenon.
Lai C; Li C; Luo X; Liu M; Liu X; Hu L; Kang L; Qiu Q; Deng Y; Song Y
Mol Pharm; 2018 Jul; 15(7):2548-2558. PubMed ID: 29768009
[TBL] [Abstract][Full Text] [Related]
3. A preliminary study of the innate immune memory of Kupffer cells induced by PEGylated nanoemulsions.
Liu M; Su Y; Chen M; Wang J; Liu M; Dai Y; Wang C; Luo X; Lai C; Liu M; Ding J; Li C; Hu Y; Tang X; Liu X; Deng Y; Song Y
J Control Release; 2022 Mar; 343():657-671. PubMed ID: 34954252
[TBL] [Abstract][Full Text] [Related]
4. Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon.
El Sayed MM; Takata H; Shimizu T; Kawaguchi Y; Abu Lila AS; Elsadek NE; Alaaeldin E; Ishima Y; Ando H; Kamal A; Sarhan HA; Ishida T
J Control Release; 2020 Jul; 323():102-109. PubMed ID: 32278827
[TBL] [Abstract][Full Text] [Related]
5. A Maleimide-Terminally Modified PEGylated Liposome Induced the Accelerated Blood Clearance Independent of the Production of Anti-PEG IgM Antibodies.
Ishima Y; Yamazaki N; Chuang VTG; Shimizu T; Ando H; Ishida T
Biol Pharm Bull; 2022; 45(10):1518-1524. PubMed ID: 36184510
[TBL] [Abstract][Full Text] [Related]
6. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
[TBL] [Abstract][Full Text] [Related]
7. Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection.
Xu H; Ye F; Hu M; Yin P; Zhang W; Li Y; Yu X; Deng Y
Drug Deliv; 2015; 22(5):598-607. PubMed ID: 24524364
[TBL] [Abstract][Full Text] [Related]
8. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes.
Ishida T; Ichihara M; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):243-50. PubMed ID: 17011060
[TBL] [Abstract][Full Text] [Related]
9. Evasion of the accelerated blood clearance phenomenon by branched PEG lipid derivative coating of nanoemulsions.
Liu M; Zhao D; Yan N; Li J; Zhang H; Liu M; Tang X; Liu X; Deng Y; Song Y; Zhao X
Int J Pharm; 2022 Jan; 612():121365. PubMed ID: 34896215
[TBL] [Abstract][Full Text] [Related]
10. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
11. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon.
Shimizu T; Ishida T; Kiwada H
Immunobiology; 2013 May; 218(5):725-32. PubMed ID: 22995937
[TBL] [Abstract][Full Text] [Related]
12. [Elucidation of accelerated blood clearance phenomenon caused by repeat injection of PEGylated nanocarriers].
Koide H; Asai T; Hatanaka K; Shimizu K; Yokoyama M; Ishida T; Kiwada H; Oku N
Yakugaku Zasshi; 2009 Dec; 129(12):1445-51. PubMed ID: 19952519
[TBL] [Abstract][Full Text] [Related]
13. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats.
Wang XY; Ishida T; Ichihara M; Kiwada H
J Control Release; 2005 May; 104(1):91-102. PubMed ID: 15866337
[TBL] [Abstract][Full Text] [Related]
14. Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles.
Zhao Y; Wang L; Yan M; Ma Y; Zang G; She Z; Deng Y
Int J Nanomedicine; 2012; 7():2891-900. PubMed ID: 22745552
[TBL] [Abstract][Full Text] [Related]
15. A higher dose of PEGylated gold nanoparticles reduces the accelerated blood clearance phenomenon effect and induces spleen B lymphocytes in albino mice.
Abu-Dief AM; Alsehli M; Awaad A
Histochem Cell Biol; 2022 Jun; 157(6):641-656. PubMed ID: 35157114
[TBL] [Abstract][Full Text] [Related]
16. Time Interval of Two Injections and First-Dose Dependent of Accelerated Blood Clearance Phenomenon Induced by PEGylated Liposomal Gambogenic Acid: The Contribution of PEG-Specific IgM.
Wang F; Ye X; Wu Y; Wang H; Sheng C; Peng D; Chen W
J Pharm Sci; 2019 Jan; 108(1):641-651. PubMed ID: 30595169
[TBL] [Abstract][Full Text] [Related]
17. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes.
Xu H; Wang KQ; Deng YH; Chen DW
Biomaterials; 2010 Jun; 31(17):4757-63. PubMed ID: 20303164
[TBL] [Abstract][Full Text] [Related]
18. Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells.
Shimizu T; Mima Y; Hashimoto Y; Ukawa M; Ando H; Kiwada H; Ishida T
Immunobiology; 2015 Oct; 220(10):1151-60. PubMed ID: 26095176
[TBL] [Abstract][Full Text] [Related]
19. Branched PEG-modification: A new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy.
Liu M; Li J; Zhao D; Yan N; Zhang H; Liu M; Tang X; Hu Y; Ding J; Zhang N; Liu X; Deng Y; Song Y; Zhao X
Biomaterials; 2022 Apr; 283():121415. PubMed ID: 35217484
[TBL] [Abstract][Full Text] [Related]
20. Activation of CYP3A by Accelerated Blood Clearance Phenomenon Potentiates the Hepatocellular Carcinoma-Targeting Therapeutic Effects of PEGylated Anticancer Prodrug Liposomes.
Zhang X; Pan J; Ye X; Chen Y; Wang L; Meng X; Chen W; Wang F
Drug Metab Dispos; 2023 Dec; 51(12):1651-1662. PubMed ID: 37775330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
